Px-104

Phenex Pharmaceuticals AG · Phase 2 active Small molecule

At a glance

Generic name	Px-104
Sponsor	Phenex Pharmaceuticals AG
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Px-104 CI brief — competitive landscape report
Px-104 updates RSS · CI watch RSS
Phenex Pharmaceuticals AG portfolio CI